Complete your Svelta Labs order
Secure card or crypto payment options, discreet dispatch details, and research-use confirmation before the order is created.
Selected product
Retatrutide Pen
Retatrutide, also known as LY3437943, is an investigational triple-receptor agonist designed to activate the GIP, GLP-1 and glucagon receptor pathways. It is currently being studied in Phase 3 clinical trials to assess its safety and efficacy in adults with obesity, overweight and associated health conditions. Retatrutide has not received UK marketing authorisation, and no commercially approved retatrutide pen is currently available. It must not be presented as an approved weight-loss treatment, supplied for self-administration or used outside an appropriately authorised clinical trial.